A groundbreaking study from Baylor College of Medicine explores how two types of CAR T cells target cancer, shedding light on ...

Because tumor cells are known to induce T-cell ... CAR transmembrane domain to enhance the immune synapse, offers an avenue for enhancing CAR-T therapy. By optimizing the immune synapse without ...

A study shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators examined how molecular dynamics at the immune synapse -- where ...

A study explores the molecular dynamics of CD28.ζ-CAR and 4-1BB.ζ-CAR T cells at the immune synapse, where CAR T cells bind ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor ...

Ahmed Gad, postdoctoral associate in Ahmed's lab, the research team examined molecular dynamics at the immune synapse. The team biopsied the CAR T cell immunological synapse by isolating the ...

CAR T cell therapy revolutionizes oncology by using engineered T cells to target and eliminate cancer cells, improving outcomes in hematological malignancies.

Non-Hodgkin lymphoma (NHL) is a blood cancer that occurs when malignant cells develop in the lymphatic system. (Image Credits: Pixabay) Immuneel Therapeutics on Monday launched Qartemi, a CAR T ...

Their new system is outlined in a paper published today in Nature Biomedical Engineering. CAR T cell therapy has revolutionized cancer care, providing a powerful option for some blood cancers.